Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 18, 2026

Visara Doses First Patient in Phase 2b Trial Pitting Bispecific VIS-101 Against Aflibercept in Wet AMD

Listen
0:00 / 0:00

Key Takeaways

  • ASCEND randomizes ~244 treatment-naïve wet AMD patients to VIS-101 6 mg, VIS-101 9 mg, or aflibercept 2 mg q8w, using quadruple masking and head-to-head active control.
  • Uniform retreatment criteria across arms through Month 9 follow three monthly loading injections, enabling comparative assessment of durability with intervals extending up to seven months post-loading.
SHOW MORE

Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.

Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, announced on November 18, 2026, that the first patient has been dosed in ASCEND, a phase 2b trial of VIS-101 in wet age-related macular degeneration (AMD).¹ VIS-101 is a tetravalent, bispecific inhibitor of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (ANG-2) designed for efficacy and durability.¹

“VIS-101 was purpose-designed with durability in mind.” Cadmus Rich, MD, MBA, chief medical officer, Visara

ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head study enrolling about 244 treatment-naïve patients with wet AMD.¹ The goal, according to Jeffrey Nau, PhD, MMS, president and chief executive officer of Visara, is to “maintain strong disease control while enabling patients to go substantially longer between injections.”¹

How is the ASCEND trial designed?

Patients are randomized to VIS-101 6 mg, VIS-101 9 mg, or aflibercept 2 mg, the standard-of-care comparator dosed every 8 weeks.¹ All patients receive three monthly loading doses, followed by retreatment based on protocol criteria that are the same across groups through Month 9.¹ The study evaluates treatment intervals of up to seven months after loading.¹

The trial is designed to determine the dose or doses for phase 3 and to establish initial durability.¹ ASCEND is being conducted in China in partnership with Everest Medicines.¹ Visara holds global rights to VIS-101 outside Greater China and certain Asian territories.²

What did earlier data show?

In a randomized, dose-ranging phase 2a study in China, 38 patients with wet AMD received VIS-101 6 mg (n = 25) or 3 mg (n = 13).² VIS-101 produced mean best-corrected visual acuity improvements of more than 10 Early Treatment Diabetic Retinopathy Study letters, and the company described the responses as rapid and durable with a favorable safety profile.² About 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose.¹

“VIS-101 was purpose-designed with durability in mind,” said Cadmus Rich, MD, MBA, chief medical officer of Visara.¹ Visara says the bispecific, tetravalent format provides more binding sites and increased affinity and avidity for VEGF-A and ANG-2.¹

Why target both VEGF-A and ANG-2?

ANG-2 is upregulated in the retina and vitreous in neovascular AMD, where it destabilizes blood vessels and sensitizes them to VEGF-A.³ Roche’s faricimab (Vabysmo), a bispecific antibody against both targets, validated the approach in the phase 3 TENAYA and LUCERNE trials, in which faricimab dosed up to every 16 weeks was noninferior to aflibercept every 8 weeks for visual acuity across 1,329 patients.³ Nearly half of faricimab-treated patients were on 16-week dosing at Week 48, and rates of ocular adverse events were comparable between the two arms.³

Developers are now working to push intervals further. BioPharm International® recently reported on Johnson & Johnson’s acquisition of Ollin Biosciences and its small-format VEGF/ANG-2 bispecific OLN324, as well as Eyconis’ long-acting anti-VEGF candidate EYC-0305.

Multispecific design is central to that push. In a BioPharm International video interview ahead of BIO 2026, Sabeen Mekan, MD, senior vice president and chief medical officer at Zymeworks, said, “Bispecific, trispecific, and multispecific formats are designed to improve targeting precision and enhance therapeutic activity by engaging multiple epitopes or biological mechanisms simultaneously.”

What happens next?

VIS-101 has completed initial safety and dose-escalation studies in the United States and China, and it is also in development for diabetic macular edema and retinal vein occlusion.¹ Visara plans to start a global phase 3 program as early as 2027.¹ The company has not disclosed when ASCEND results are expected.

References

  1. Visara announces first patient dosed in ASCEND phase 2b trial of VIS-101 in wet AMD. News release. NovaBridge Biosciences; November 18, 2026. Accessed November 18, 2026.
  2. NovaBridge and Visara announce positive results from VIS-101 phase 2a wet AMD study. News release. NovaBridge Biosciences; March 9, 2026. Accessed November 18, 2026.
  3. Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1

Related to this article